{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-009999","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2026-09-10T21:24:54+00:00","discovered_at":"2026-09-10T21:26:00.554650+00:00","generated_at":"2026-09-10T21:26:04.884279+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kala Bio secures exclusive US distribution rights for Virotek ophthalmology genetic testing program","bullets":["Exclusive 5-year distribution deal with Virotek for ophthalmology genetic testing/screening program in US, effective Sept 3, 2026.","Profit split 50/50 after Virotek recovers COGS; Kala handles commercial development, Virotek delivery/administration.","Exclusivity conditioned on Kala meeting milestone by Sept 3, 2027; failure converts to non-exclusive after 30-day cure.","Kala gets right of first refusal on any sale/license of Virotek's ophthalmology products; term renewable by mutual agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-009999","json":"https://secwatch.observer/filing/0001829126-26-009999.json","markdown":"https://secwatch.observer/filing/0001829126-26-009999.md","text":"https://secwatch.observer/filing/0001829126-26-009999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/0001829126-26-009999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/kalabio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T21:26:04.884279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}